| Brent Saunders | |
| Birth Date: | February 6, 1970 |
| Alma Mater: | Bachelor's, University of Pittsburgh[1] MBA, Temple University JD, Temple University |
| Occupation: | Chairman and CEO of Bausch + Lomb Founder of Vesper Healthcare Acquisition Chairman of The Beauty Health Company Chairman of Hugel America |
| Known For: | Biopharma executive, entrepreneur[2] |
Brent Saunders is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb. He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie. He is the founder of special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition. Saunders is also executive chairman of medical aesthetics companies The Beauty Health Company and Hugel America.
Saunders was born in to Charles and Sheila Saunders, a urologist and social worker.[1] [3] He grew up in the Lehigh Valley region of eastern Pennsylvania, with a twin brother Wayne and sister Reed,[1] and graduated from Parkland High School in South Whitehall Township, Pennsylvania in 1988.[1]
He attended the University of Pittsburgh, where he was president of the student government board,[1] and graduated in 1992 with a bachelor's degree in economics and East Asian studies.[1] In 1996, he received MBA and J.D. degrees from Temple University in Philadelphia.[1]
In 1996, while attending law school, Saunders started working part time at Jefferson Health as a compliance officer.[1]
In 2000, Saunders joined PricewaterhouseCoopers as a healthcare compliance manager, and became partner and head of the firm's compliance business advisory services group.[1] In October 2003, Saunders was hired as senior vice president of global compliance and business practices at Schering-Plough, a pharmaceutical company.[1] In mid-2007, he became president of consumer health care at Schering-Plough, with responsibility for a business unit of products including Coppertone, Dr. Scholl's, and Claritin.[1] In 2009, Saunders led the integration team of Schering-Plough's merger with Merck.
In 2010, Saunders was appointed chief executive officer Bausch & Lomb, an eye health company.[4] In 2010 he was appointed to the Federal Reserve advisory board.[5] In 2013, as CEO of Bausch + Lomb, he oversaw its acquisition by Valeant Pharmaceuticals, now known as Bausch Health, for $8.7 billion. He joined Valeant in an advisory role to assist with the transition.[6] In October, Saunders joined pharmaceutical company Forest Laboratories as CEO.[7]
In May 2014, Saunders was named chief executive officer of Actavis, a pharmaceutical company, after the company acquired Forest Laboratories.[8] In November, Saunders negotiated Actavis' merger with Allergan, a pharmaceutical company, for a reported $70.5 billion.[1] The new combined company took the Allergan name.[9]
In February 2015, Saunders appeared on the cover of Forbes magazine, where he was named as "Wall Street's Drug Dealer".[3] In May 2019, Saunders survived a proposal brought by hedge fund Appaloosa Management to split Allergan's chairman and CEO roles.[10] In June, pharmaceutical company Abbvie acquired Allergan for $63 billion.[11]
In June 2020, Saunders joined the board of BridgeBio Pharma, a company founded with an IPO in 2019.[12] In September, Saunders’ special-purpose acquisition company Vesper Healthcare Acquisition publicly launched, and raised $400 million.[13] Filings indicated that Saunders owned 20% of the company after the SPAC sale.[13] In December, Saunders made his first deal with Vesper, acquiring HydraFacial, a beauty treatment company, for $1.1 billion.[14]
In May 2021, Vesper's HydraFacial deal closed, and the new company was renamed The Beauty Health Company, with Saunders taking the role of executive chairman.[15] He also served as interim CEO until February 2022.[16]
In June 2022, Saunders was named to the board of medical aesthetics company Hugel America, an affiliate of South Korea-based Hugel Inc.[17]
In March 2023, Saunders returned to Bausch + Lomb as CEO and chairman.[18] In June, Saunders signed his first deal as CEO, purchasing dry eye drug Xiidra from Novartis for $1.75 billion.[19]